Suspected adverse drug reactions, principally in Scandinavia, prompted the EU to suspend marketing authorisation for Econor in October 2000. A series of extensive investigations were immediately launched by Novartis Animal Health, which have helped to explain the mysterious findings and has led to the successful licence reinstatement of the swine antibiotic.